Triangle formation Immunovia- BLUE - Possible stock price improvement, based on the theory of triangles.
- YELLOW - Triangle hypotenuse that can't be crossed if formation is to be completed.
- RED - Triangle roof that can give a buy signal if crossed.
Wanted to share with you what I found in the chart. This is n
−8.272SEK
−309.42 MSEK
1.57 MSEK
44.05 M
About IMMUNOVIA AB
Sector
CEO
Jeff Borcherding
Headquarters
Lund
Website
Founded
2007
ISIN
SE0006091997
FIGI
BBG00BKSX594
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of IMMNOV is 1.828 SEK — it has increased by 2.24% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange IMMUNOVIA AB stocks are traded under the ticker IMMNOV.
IMMUNOVIA AB is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
IMMNOV stock is 2.20% volatile and has beta coefficient of −0.81. Check out the list of the most volatile stocks — is IMMUNOVIA AB there?
IMMUNOVIA AB revenue for the last quarter amounts to 358.00 K SEK despite the estimated figure of 800.00 K SEK. In the next quarter revenue is expected to reach 2.00 M SEK.
Yes, you can track IMMUNOVIA AB financials in yearly and quarterly reports right on TradingView.
IMMNOV stock has risen by 0.44% compared to the previous week, the month change is a 32.85% rise, over the last year IMMUNOVIA AB has showed a 61.52% decrease.
IMMNOV net income for the last quarter is −49.00 M SEK, while the quarter before that showed −38.56 M SEK of net income which accounts for −27.09% change. Track more IMMUNOVIA AB financial stats to get the full picture.
Today IMMUNOVIA AB has the market capitalization of 80.97 M, it has increased by 7.99% over the last week.
No, IMMNOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, IMMNOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IMMUNOVIA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IMMUNOVIA AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IMMUNOVIA AB stock shows the sell signal. See more of IMMUNOVIA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.